Background and Objective: The aim of this research was to study the correlation between daily stresses and coping styles with mental health in migraine headache patients. Materials and Methods: The research method was comparative-casual method. The sample consisted of 60 patients with migraine headaches (30 males and 30 females) as the test group, whom were matched for various criteria including age, educational status, and suffering from headache for at least a two year period. The control group consisted of 60 healthy school teachers (30 males and 30 female). The instruments included Lazarous–Folkman Coping Style, Holms-Rahe life stress, and General Health questionnaires. The data were analyzed with the logistic regression method. Results: The results revealed that there was a significant difference between the test and control groups in daily stresses and coping styles (p<0.001). Furthermore, the rate of stresses in patients with migraine headache was significantly higher than the normal subjects. In addition, the rate of emotional styles in patients with migraine headache was higher than normal controls. Conclusion: There was a negative correlation between daily stresses, emotional styles, and mental health in patients with migraine headache.

Background and Objective: Migraine is a neurological syndrome that involves one-way or two-way recurrent headaches with a moderate to severe severity and lasts from 2 to 72 hours. Chronic migraines occur for about 3 months and at least 15 days or more per month, with a global incidence of 1.4 to 2.2 percent. The aim of this study was to compare the effectiveness of neurofeedback and transcranial direct current stimulation (tDCS) in reducing symptoms of women with migraine.
Materials and Methods: This is a quasi-experimental study with pre-test, post-test, and follow-up for 2 months. The sample consisted of 20 migraine patients aged 15-55 years. Initial evaluation (entrance examination and exit), implementation of the Ahvaz Migraine Questionnaire (AMQ), and Blanchard Headache Diary (BHD) were performed. Patients were randomly assigned to the neurofeedback treatment group (N=10) and tDCS (N=10). Subjects of each group were evaluated 4 times consisting before intervention. The data were analyzed using SPSS 23 software.
Results: The results of Mann-Whitney U test indicated that there was no significant difference between the two treatments during the stages of evaluation in the severity, duration, and number of pain attacks per month. The results of Friedman test showed that there was a significant difference between the severity of headaches and the number of pain attacks in one month in the treatment groups during the stages of evaluation, but the duration of pain relief in each group in the evaluation steps did not differ significantly.
Conclusion: Neurofeedback and tDCS treatments reduce the symptoms of migraine disease, but there is no significant difference between the two treatments in terms of headache symptoms improvement.

 Background & Objective:  Migraine is an occasional headache that represents neurological and gastrointestinal symptoms, as well as changes in the autonomic nervous system. Biofeedback is a non-pharmacological technique used to treat migraine headaches and is proven to reduce headaches and improve performance. The present study aimed to compare the efficacy of biofeedback and pharmacological treatments to find the best treatment strategy for migraine headaches.
 Materials & Methods:  This randomized clinical trial was performed on 86 patients who referred to Noor Psychiatric Clinic and Neurology Clinic of Valiasr Hospital, Zanjan, Iran. Patients were divided into two groups of daily treatment with medication and treatment with medicine and biofeedback. Cases were monitored every two months using interviews and questionnaires.
 Results:  The study was carried out on 86 migraine patients with the age range of 31-45 years for 3 months. Most of the patients were female, including 90.7% of the individuals in the case group and 81.4% of the control group. The frequency distribution of medication use was not different between the two groups (P=0.744). Most of the participants had a history of more than 1 year of headache. During the treatment, the frequency and severity of attacks reduced obviously until the 8^th week. The decrease in the Migraine Disability Assessment (MIDAS) score was more significant in the biofeedback group, except in the 10^th and 12^th weeks. However, the decline in the MIDAS score was not significant. Moreover, the reduction in the frequency of attacks remained significant until the end of the study.
 Conclusion:  It can be concluded that the combination of biofeedback treatment and medication therapy provides a more rapid response than pharmacological treatment alone. Therefore, biofeedback is an effective add-on therapy, which can be taken into consideration for diminishing all aspects of migraine headache attacks.

Background and Objective: Migraine is a common neurological disorder affecting one billion people worldwide, causing disability, reduced quality of life, and high economic costs. Medical treatments have often limited efficacy and side effects. Non-pharmacological options such as trigeminal nerve stimulation with devices such as Cefaly® offer alternatives. This study assesses effectiveness of Cefaly®'s in reducing uncontrolled migraine symptoms alongside standard medications.
Methods: This study included 20 patients with migraine, with or without aura, intractable to conventional treatments. Participants used the Cefaly® device in addition to regular medication for external trigeminal nerve stimulation on the forehead. Migraine frequency, severity, and duration were assessed over one month using pre- and post-intervention questionnaires, with data analyzed by nonparametric methods due to the small sample size.
Results: The proportion of participants experiencing severe attacks dropped from 45% to 15% (P = 0.037). The frequency of attacks was reduced, with the percentage of participants having 3-5 attacks per month falling from 75% to 45%, and those with more than 5 attacks per month declining to 0% (P = 0.038). Attack duration also decreased, with a reduction in attacks lasting 12-24 hours from 35% to 20%, and those lasting more than 24 hours from 45% to 15% (P = 0.002).
Conclusion: Cefaly® could effectively reduce the severity, frequency, and duration of headaches in patients who do not respond conventional treatments, suggesting it as a promising non-pharmacological option. Further research with larger samples and longer follow-up is needed to confirm these findings and assess long-term efficacy.